19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Label‐free proteomic dissection on dptP‐deletion mutant uncovers dptP involvement in strain growth and daptomycin tolerance of Streptomyces roseosporus

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The combination of label‐free quantification proteomic dissections with loss‐ and gain‐of‐function experiments was carried out to decipher dptP‐involved functions. DptP gene contributes to Streptomcyes primary growth under elevated temperature and DAP treatment, whereas it plays negative roles on metabolism of secondary metabolites and transcription of DAP biosynthetic genes. The strategies used in this study provide references for the follow‐up study on other relative genes of dpt gene cluster and metabolic pathway optimization for S. roseosporus.

          Summary

          Daptomycin (DAP) is a novel microbial lipopeptide antibiotic synthesized by the DAP biosynthetic gene cluster dpt of Streptomyces roseosporus (S. roseosporus). DptP gene locates upstream of dpt and confers DAP resistance to Streptomyces ambofaciens (S. ambofaciens). So far, the biological functions of dptP gene for S. roseosporus growth are still completely uncovered. We performed label‐free quantification proteomic dissections with loss‐ and gain‐of‐function experiments to decipher dptP‐involved functions. Deletion of dptP gene activated energy metabolism and metabolism of secondary metabolites pathways and enhanced the transcription levels and protein abundance of key members of the dpt cluster. Whereas dptP deletion inhibited transport/signal transduction and drug resistance pathways and protein abundance of cell division‐relative proteins, subsequently decreased mycelia cell growth rate. S. roseosporus strain with dptP deletion was more sensitive to DAP treatment compared to the wild type. In contrast, overexpression of dptP gene decreased transcription levels of DAP biosynthetic genes and enhanced growth rate of Streptomcyes strain upon elevated culture temperature and DAP supplementation. Taken together, dptP gene contributes to Streptomcyes primary growth under elevated temperature and DAP treatment, whereas it plays negative roles on metabolism of secondary metabolites and transcription of DAP biosynthetic genes.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          Universal sample preparation method for proteome analysis.

          We describe a method, filter-aided sample preparation (FASP), which combines the advantages of in-gel and in-solution digestion for mass spectrometry-based proteomics. We completely solubilized the proteome in sodium dodecyl sulfate, which we then exchanged by urea on a standard filtration device. Peptides eluted after digestion on the filter were pure, allowing single-run analyses of organelles and an unprecedented depth of proteome coverage.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp.

            We have constructed cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. All vectors contain the 760-bp oriT fragment from the IncP plasmid, RK2. Transfer functions need to be supplied in trans by the E. coli donor strain. We have incorporated into these vectors selectable antibiotic-resistance markers (AmR, ThR, SpR) that function in Streptomyces spp. and other features that should allow for: (i) integration via homologous recombination between cloned DNA and the Streptomyces spp. chromosome, (ii) autonomous replication, or (iii) site-specific integration at the bacteriophage phi C31 attachment site. Shuttle cosmids for constructing genomic libraries and bacteriophage P1 cloning vector capable of accepting approx. 100-kb fragments are also described. A simple mating procedure has been developed for the conjugal transfer of these vectors from E. coli to Streptomyces spp. that involves plating of the donor strain and either germinated spores or mycelial fragments of the recipient strain. We have shown that several of these vectors can be introduced into Streptomyces fradiae, a strain that is notoriously difficult to transform by PEG-mediated protoplast transformation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Natural product and natural product derived drugs in clinical trials.

              There are a significant number of natural product (NP) drugs in development. We review the 100 NP and NP-derived compounds and 33 Antibody Drug Conjugates (ADCs) with a NP-derived cytotoxic component being evaluated in clinical trials or in registration at the end of 2013. 38 of these compounds and 33 ADCs are being investigated as potential oncology treatments, 26 as anti-infectives, 19 for the treatment of cardiovascular and metabolic diseases, 11 for inflammatory and related diseases and 6 for neurology. There was a spread of the NP and NP-derived compounds through the different development phases (17 in phase I, 52 in phase II, 23 in phase III and 8 NDA and/or MAA filed), while there were 23 ADCs in phase I and 10 in phase II. 50 of these 100 compounds were either NPs or semi-synthetic (SS) NPs, which indicated the original NP still plays an important role. NP and NP-derived compounds for which clinical trials have been halted or discontinued since 2008 are listed in the Supplementary Information. The 25 NP and NP-derived drugs launched since 2008 are also reviewed, and late stage development candidates and new NP drug pharmacophores analysed. The short term prospect for new NP and NP-derived drug approvals is bright, with 31 compounds in phase III or in registration, which should ensure a steady stream of approvals for at least the next five years. However, there could be future issues for new drug types as only five new drug pharmacophores discovered in the last 15 years are currently being evaluated in clinical trials. The next few years will be critical for NP-driven lead discovery, and a concerted effort is required to identify new biologically active pharmacophores and to progress these and existing compounds through pre-clinical drug development into clinical trials.
                Bookmark

                Author and article information

                Contributors
                yunzi.luo@tju.edu.cn
                zizi2006@scu.edu.cn
                Journal
                Microb Biotechnol
                Microb Biotechnol
                10.1111/(ISSN)1751-7915
                MBT2
                Microbial Biotechnology
                John Wiley and Sons Inc. (Hoboken )
                1751-7915
                24 December 2020
                March 2021
                : 14
                : 2 , Special Issue on Advances in Microbial Biotechnology in China ( doiID: 10.1111/mbt2.v14.2 )
                : 708-725
                Affiliations
                [ 1 ] State Key Laboratory of Biotherapy and Cancer Center Collaborative Innovation Center for Biotherapy West China Hospital Sichuan University Chengdu 610041 China
                [ 2 ] Key Laboratory of Leather Chemistry and Engineering Ministry of Education and College of Light Industry Textile and Food Engineering Sichuan University Chengdu 610065 China
                [ 3 ] Key Laboratory of Systems Bioengineering (Ministry of Education) School of Chemical Engineering and Technology Tianjin University Tianjin 300072 China
                Author notes
                [*] [* ] For correspondence *E‐mail zizi2006@ 123456scu.edu.cn ; Tel. +13 008 152730; Fax +028‐85 502 796.

                For correspondence **E‐mail: yunzi.luo@ 123456tju.edu.cn , Tel.18608011365; Fax +86‐22‐27403389.

                [†]

                These authors contributed equally to this study.

                Author information
                https://orcid.org/0000-0003-1000-7508
                Article
                MBT213736
                10.1111/1751-7915.13736
                7936300
                33369164
                fdf1dbed-fb58-4957-afb2-450ebad90067
                © 2020 Sichuan University. Microbial Biotechnology published by Society for Applied Microbiology and John Wiley & Sons Ltd

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 05 July 2020
                : 07 December 2020
                Page count
                Figures: 9, Tables: 1, Pages: 18, Words: 9298
                Funding
                Funded by: Sichuan Science & Technology Program
                Award ID: 2020YFH0094
                Funded by: Chengdu Science & Technology Program
                Award ID: 2020‐GH02‐00056‐HZ
                Funded by: Health Commission of Sichuan Province
                Award ID: 17ZD045
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                March 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.9 mode:remove_FC converted:06.03.2021

                Biotechnology
                Biotechnology

                Comments

                Comment on this article